Funding: Supported by NIH funding (R01DK069418) and startup fund from Sichuan University to YPH, China National Key Project of the Twelfth Five-Year Plan (2012ZX10002004-006), Beijing Chaoyang District, AIDS and Viral Hepatitis Beijing (2012ZX10004904-003-001) to DZP, Beijing New Star Project on Science and Technology (2007B055) to ZSJ.
Vitamin D in liver diseases: From mechanisms to clinical trials
Version of Record online: 15 JUL 2013
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd
Journal of Gastroenterology and Hepatology
Special Issue: 7th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis. Funding for this conference was made possible (in part) by Grant 5 R13AA20691-02 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Guest Editors: Bin Gao and Fu-Sheng Wang
Volume 28, Issue Supplement S1, pages 49–55, August 2013
How to Cite
Han, Y.-P., Kong, M., Zheng, S., Ren, Y., Zhu, L., Shi, H. and Duan, Z. (2013), Vitamin D in liver diseases: From mechanisms to clinical trials. Journal of Gastroenterology and Hepatology, 28: 49–55. doi: 10.1111/jgh.12016
- Issue online: 15 JUL 2013
- Version of Record online: 15 JUL 2013
- Manuscript Accepted: 3 NOV 2012
- NIH. Grant Number: R01DK069418
- Sichuan University
- China National Key Project of the Twelfth Five-Year Plan. Grant Number: 2012ZX10002004-006
- Beijing Chaoyang District
- AIDS and Viral Hepatitis Beijing. Grant Number: 2012ZX10004904-003-001
- Beijing New Star Project on Science and Technology. Grant Number: 2007B055
- alcoholic liver diseases (ALD);
- fatty liver;
- liver diseases;
- vitamin D;
- vitamin D deficiency.
Traditionally regarded as a typical vitamin regulating calcium and phosphorus homeostasis, vitamin D is now discovered as a highly versatile molecule with emerging roles in immunity, cancer, infectious diseases, fibrosis, fatty liver diseases, and alcoholic liver diseases. A large body of clinical evidence has demonstrated the prevalence and risks of vitamin D deficiency in various chronic diseases. Biologically active vitamin D, 1,25-dihydroxylvitamin D3, is synthesized in two distinct systems. In addition to the classic two-step hydroxylation in the liver and kidneys, 1,25-dihydroxylvitamin D3 can also be produced locally by immune cells in response to infection. The bioactive vitamin D generated in these two pools apparently functions differently: while the former facilitates calcium adsorption and homeostasis, the latter confers immune regulation. The immune regulatory functions of vitamin D are demonstrated by induction of antimicrobial peptides, suppression of innate immune response, induction of Th2 cytokines, and stimulation of T-regulatory T cells. Vitamin D deficiency or insufficiency is overwhelmingly associated with viral hepatitis, cirrhosis, and fatty liver diseases. Recent clinical trials have shown that vitamin D supplements significantly enhance the efficacy of interferon plus ribavirin therapy through sustained virological response. A recent study showed that 25-dihydroxyvitamin D rather than 1,25-dihydroxyvitamin D could directly suppress hepatitis C virus assembly. Moreover, clinical evidence has shown that vitamin D deficiency is associated with alcoholic and non-alcoholic fatty liver diseases. In this review, we highlight some recent advances in vitamin D researches and clinical trails.